|Home | About | Journals | Submit | Contact Us | Français|
Respiratory infections are associated with wheezing illnesses in all ages and may also impact the development and severity of asthma. Respiratory tract infections caused by viruses, Chlamydophila or Mycoplasma have been hypothesized to have significant roles in the pathogenesis of asthma. Progress is being made toward establishing the mechanisms by which these agents can cause acute wheezing and impact the pathophysiology of asthma. Host factors probably contribute to the risk of asthma inception and exacerbation, and these contributions may also vary with respect to early- versus adult-onset disease. This review discusses these various associations as they pertain to the development and exacerbation of asthma.
Respiratory infections are associated with wheezing illnesses at all ages and may also impact the development and severity of asthma. Respiratory tract infections caused by viruses [1–3], Chlamydophila [4–7] or Mycoplasma [5,8–10] have been hypothesized to have significant roles in the pathogenesis of asthma. Of these respiratory pathogens, viruses have been shown to be epidemiologically associated with asthma in several ways. First, particular viruses associated with infantile wheezing have been theorized to lead to the inception of the asthmatic phenotype [11,12]. Second, children who experience severe viral respiratory infections in early life are more likely to have asthma later in childhood [3,11,13]. Furthermore, in children and adults with established asthma, viral upper respiratory tract infections (URIs) play a key role in producing acute exacerbations that may lead to healthcare utilization [14–16]. Several host factors, such as allergic sensitization [14,17] and virus-induced interferon responses [18–20], modify the risk of virus-induced wheezing. For infections with other microbes, interest has focused on Chlamydophila and Mycoplasma as possible contributors to both acute exacerbations and the severity of chronic asthma [5,7]. Finally, colonization of the upper airways in infancy with common bacterial pathogens has been demonstrated to increase the risk of subsequent asthma . We review these various associations as they pertain to the development and exacerbation of asthma.
Several studies have documented that the incidence of asthma peaks in early childhood with rates as high as five new cases per 1000 population per year, more commonly in boys [22–24]. Incidence declines in adolescence and then climbs again in early adulthood, with a reversal of gender predilection favoring women after the onset of puberty [22–25]. Whereas eczema and a family history of asthma are the dominant noninfectious risk factors for pediatric asthma, the triggers of adult-onset disease are less well defined [26–28]. Occupational exposures and a personal history of smoking contribute in a minority of cases, whereas either allergic or nonatopic rhinitis has been associated with adult onset disease in multiple studies [29–32]. With respect to remission rates, there is up to a 63% chance of remission of asthma in patients who develop disease before 10 years of age, but only 5–15% for adult-onset disease [24,33]. This is consistent with the notion that pediatric and adult asthma may have some important clinical differences, with the latter having a higher incidence of steroid resistance and more complicated management [34,35]. Nonetheless, respiratory infection is the most common acute inflammatory trigger in incident asthma .
Two of the most common viral illnesses leading to lower respiratory tract infection (LRI) and wheezing in infancy are those caused by respiratory syncytial virus (RSV) and human rhinoviruses (HRVs). Using multiple virus detection methods, Jartti and colleagues determined the etiology of wheezing illness in 293 hospitalized children . Out of the 76 infants with virus detected, 54% had RSV, 42% had picornavirus (HRV and enterovirus) and 1% had human metapneumovirus (hMPV). From 1980 to 1996, the rates of hospitalization of infants with bronchiolitis increased substantially  and RSV was the etiology in approximately 70% of these episodes. In older children, respiratory picornaviruses dominated (65% of children aged 1–2 years and 82% of children aged ≥3 years) .
However, bronchiolitis is a severe form of RSV infection that occurs in a minority of children. By 1 year of age, 50–65% of children will have been infected with this virus, and by 2 years of age nearly 100% have been infected . Children 4 months of age and born close to the onset of the viral season have a higher likelihood of developing lower respiratory tract symptoms [40,41], and this is likely due to an airway, lung parenchyma and/or immunologic maturation . Furthermore, a child born 4 months before the winter virus peak predicts an increased risk of childhood asthma . Additional risk factors for bronchiolitis include antiviral immune responses (both innate  and adaptive ), gender, lung size and passive smoke exposure .
Several large, prospective studies of children have demonstrated that RSV bronchiolitis is an important risk factor for recurrent wheezing and asthma during the first decade of life [12,44]. A longitudinal, population-based cohort study has shown that the association between RSV LRIs and both frequent (> three episodes) and infrequent (< three episodes) wheezing diminish markedly with age and becomes nonsignificant by 13 years of age, whereas the early RSV negative, other infectious agent group continued to confer risk of frequent wheezing . This decreased association between wheezing and RSV LRI with increasing age has also been observed by other investigators [45,46]. These data suggest that although RSV infections increase the risk of recurrent wheezing and asthma in early childhood, other genetic, environmental and developmental factors modify the expression of the asthma phenotype over time.
Although bronchiolitis during infancy is associated with an approximately twofold increased risk of early childhood asthma, this risk differs by season of bronchiolitis. Bronchiolitis occurring during HRV-predominant months (Spring and Fall) was associated with an estimated 25% increased likelihood of early childhood asthma compared with RSV-predominant (Winter) months. However, the proportion of associated asthma after winter season bronchiolitis is greater than HRV-predominant months owing to the larger numbers of children affected by RSV bronchiolitis . Similarly, it has been shown that 16.6% of children with non-RSV bronchiolitis develop recurrent wheezing, compared with 2.5% of children with RSV bronchiolitis . Another study by Kusel and coworkers demonstrated that, although RSV was associated with more severe LRI requiring hospitalization, HRV was associated with more than three-times the number of both wheezing and nonwheezing LRI in infancy . In addition, these authors found that acute severe LRI caused by HRV or RSV in the first year of life were strongly associated with the diagnosis of current asthma and persistent wheeze in 5-year-old children, particularly in those who are sensitized during infancy. Jackson and coworkers also demonstrated that in a large, high-risk cohort, children had an increased risk of asthma at 6 years of age if they wheezed in the first 3 years of life with RSV (odds ratio [OR]: 2.6), HRV (OR: 9.8), or both HRV and RSV (OR: 10) . By 3 years of age, wheezing with HRV (OR: 25.6) was more strongly associated with asthma at 6 years of age than aeroallergen sensitization (OR: 3.4). Similarly, this strong association of early-life HRV wheezing and increased risk of recurrent wheeze [49,50] and asthma  has been demonstrated in several studies. These findings support the concept that HRV is an important cause of bronchiolitis and is strongly associated with the risk of asthma development.
Host factors such as allergic sensitization or decreased lung function in infancy may also influence the development of recurrent wheeze and/or asthma. Premorbid measurements of lung function indicate that children with reduced levels of lung function in infancy appear to be at an increased risk of the development of chronic lower respiratory tract sequelae after viral infections  and an obstructive pattern of lung function into adulthood . Whether reduced lung function alone is responsible for these developments is presently unknown. Children with early allergic sensitization (<2 years of age) were more likely to be diagnosed with current wheeze or asthma if they had an LRI with RSV or HRV in infancy . Thus, viral infections act synergistically with allergic sensitization and reduced lung function in infancy, leading to asthma in later life.
The association between viral infections and asthma exacerbations has been illuminated by the development of sensitive diagnostic tests based on PCR and/or microarray technology, for viruses that are difficult to culture, such as HRV, hMPV and bocaviruses. With the advent of these more sensitive diagnostic tools, information linking common cold infections with exacerbations of asthma has come from a number of sources. Prospective studies of subjects with asthma have demonstrated that up to 85–95% of exacerbations of wheezing or asthma in children are caused by viral infection [16,54]. This rate is as high as 60% for adults with seasonal trends that occur 1–2 weeks later than in children, suggesting household transmission of the same strain [15,55–57]. HRVs are most often detected, especially during the Spring and Fall seasons. Indeed, the Spring and Fall peaks in asthma hospitalizations correlate with patterns of HRV detection within the community . HRV infections are frequently found in children older than 2 years of age who present to emergency departments with acute wheezing  and in children hospitalized for acute asthma . A newly discovered HRV species, HRV-C, is associated with asthma flares in children during the Fall and Winter [59–61], and new strains of HRV and coronaviruses have been identified by the Virochip method in adults . RSV is more likely to trigger acute asthma symptoms in the wintertime but likely account for a smaller proportion of overall asthma exacerbations. Influenza infections are also associated with increased healthcare utilization among children with asthma compared with healthy children . Bocaviruses have been associated with up to 19% of acute wheezing episodes in children . Other viruses that are less frequently associated with exacerbations of asthma include metapneumovirus and coronaviruses . Together, these studies provide evidence of a strong relationship between viral infections, particularly those due to HRV, and acute exacerbations of asthma.
It has been hypothesized that chronic viral and bacterial infections or colonization with pathogenic bacteria could lead to chronic lower airway inflammation, impaired mucociliary clearance, increased mucous production and eventually asthma [21,65]. Organisms implicated in this progression include adenoviruses , Chlamydophila pneumoniae [4,5,7], Mycoplasma pneumoniae [8–10], Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis . With respect to the former, latent adenoviral infection can persist in the airway for many years , where a latent infection is defined by when a virus inserts part of the virus genome into the host cell DNA and continues to periodically express viral genes. It has been demonstrated that 94% of children with steroid-resistant asthma had detectable adenovirus antigens compared with 0% of controls . In adults, both with and without asthma, evidence of adenoviral infection has been observed to be as high as 50% of the individuals tested . There is more literature regarding the association between chronic Mycobacterium or Chlamydophila infection and asthma in children and adults; however, these studies have produced contradictory results, probably due to the limitations of current diagnostics. Findings of diagnostic tests in the upper and lower airways do not always agree, and the diagnosis of infection by serology can be imprecise.
Previously, the first relationship between asthma and C. pneumoniae was described in 1991 in 19 wheezing adult asthmatic patients, of whom nine were found to have serologic evidence of current or recent infection with this pathogen . In school-age children with wheezing, a surprisingly high prevalence of low-grade C. pneumoniae infection in nasal aspirates has been observed . The detection of C. pneumoniae infection by PCR and serology (secretory IgA) was similar during symptomatic and asymptomatic episodes (23 vs 28%, respectively). Children who experienced multiple episodes also tended to remain PCR positive for C. pneumoniae, suggestive of chronic infection. Moreover, C. pneumoniae-specific secretory IgA antibody levels were more than seven-times higher in subjects who reported four or more exacerbations in the study compared with those who reported just one. In a study of 70 pediatric patients by flexible fiber optic bronchoscopy, 40% of PCR C. pneumoniae-positive samples were from patients with asthma. Culture of the blood samples revealed that a significantly higher proportion of asthma subjects (34.3%) were positive for Chlamydia compared with matched nonrespiratory control subjects (11%) . It is possible that chronic Chlamydophila infection promotes persistent airway inflammation that increases susceptibility to other stimuli such as viruses, allergens, or both associated with asthma exacerbations.
A comprehensive evaluation of the role of both Chlamydophila and Mycoplasma infections in chronic asthma was reported by Johnston et al. . The authors concluded that although many studies investigating the association between asthma and these pathogens have been uncontrolled and have provided conflicting evidence, there are biological mechanisms that could account for such a link, and that there may be a role of antibacterial therapy in the management of asthma. Martin et al. evaluated 55 adult patients with chronic asthma (percent predicted forced expiratory volume in 1 s [FEV1] = 69.3 [2.1%]), and 11 controls for infection with Mycoplasma, C. pneumoniae and viruses (influenza A and B, parainfluenza 1, 2 and 3, RSV, HRV and adenovirus) were evaluated . Bronchoalveolar lavage cell count and differential as well as tissue morphometry were also performed. Of the asthmatic patients, 56% had a positive PCR for M. pneumoniae (n = 25) or C. pneumoniae (n = 7), which was mainly found in lavage fluid or biopsy samples. Only one of 11 control subjects had a positive PCR for Mycoplasma. A significantly greater number of tissue mast cells were observed in the group of patients who were positive on PCR compared with those that were negative. Cultures for both organisms were negative in all patients, and serologic confirmation had poor correlation with PCR results. In another study by Biscardi et al., 119 children aged 2–15 years with asthma hospitalized for a severe asthma exacerbation were tested for acute infection due to M. pneumoniae or C. pneumoniae by serologic testing . Nasopharyngeal aspirate PCR was also performed. Acute M. pneumoniae infection by positive serology was found in 20% and C. pneumoniae infection was found in 3.4% of the patients during the current exacerbation. Out of 51 patients experiencing their first asthma flare, acute M. pneumoniae infection was demonstrated in 50% and C. pneumoniae in 8.3% of the patients. Out of the children infected with M. pneumoniae or C. pneumonia and experiencing their first asthma exacerbation, 62% had recurrent asthma but only 27% without these infections had recurrent asthma . Similar to the previous study, serologic confirmation correlated poorly with PCR results. Thus, chronic Chlamydophila infection may promote ongoing airway inflammation.
Some investigators have theorized as a mechanism that the development of C. pneumoniae-specific IgE antibody facilitates the release of mediators that cause bronchospasm, airway inflammation and airway reactivity . Unless infection is treated, antigenic stimulation promoting specific IgE production would continue, thus producing the prolonged course of asthma in some patients that is unresponsive to bronchodilators and steroids . The major C. pneumoniae antigen, heat-shock protein 60 (cHSP60), has been implicated in the stimulation of deleterious immune responses in human chlamydial infections. It has been observed to colocalize with infiltrating macrophages in atheromatous lesions. cHSP60 was reported to be a powerful inducer of macrophage inflammatory responses mediated through the innate immune receptor complex Toll-like receptor (TLR)4–MD2 . Taken together, these findings imply that chronic asymptomatic chlamydial infections may affect persistent airway inflammatory responses through both innate and adaptive immune responses.
As stated previously, M. pneumoniae has also been associated with both acute and chronic asthma. Again, the results of trials have been contradictory and investigators have not been able to firmly establish a causal relationship between mycoplasmal infections and asthma exacerbations. Although some have reported infection in up to 25% of children with wheezing , others have not been able to confirm these observations . Moreover, when the same group of children was evaluated for the relative contributions of mycoplasmal (and chlamydial) infections to acute exacerbations, viruses were a far more common etiology [12,69]. It is possible that this association may become more established as more sensitive and specific serologic diagnostic tests become available and/or culture techniques improve.
Unlike the inconsistent relationship between Mycoplasma species and acute asthma exacerbations, associations of this pathogen with chronic asthma have been more firmly established. As previously mentioned, using PCR techniques on bronchial biopsy specimens, Mycoplasma species have been detected in 25 out of 55 adult asthmatic subjects and in only one out of 11 controls [40, 65]. Case reports of chronic asthma commencing with M. pneumoniae infection suggest that this pathogen is a potentially causative agent in some patients . Potential mechanisms of Mycoplasma-induced airway inflammation have been explored, including augmented Th2 responses and inflammatory neuropeptides. Children with acute M. pneumonia have an elevated IL-4/IFN-γ ratio compared with children with pneumococcal pneumonia or controls , and mice experimentally infected with M. pneumoniae develop airway hyperresponsiveness (AHR), which is associated with the diminished production of mRNA for IFN-γ . Last, asthmatic patients with M. pneumoniae infection detected by PCR have increased levels of neurokinin-1, which decreases in response to treatment with a macrolide antibiotic .
The microbiome of the lower airway has not been thoroughly evaluated to date, but there is a growing sense that it is not a sterile compartment, and that its constituents may differ between healthy persons and patients with asthma. A recent study by Bisgaard and coworkers found that neonates colonized in the hypopharyngeal region with S. pneumoniae, H. influenzae or M. catarrhalis, or with a combination of these organisms, are at increased risk for recurrent, early-life wheezing and asthma at 5 years of age . Although these preliminary studies are intriguing, additional data are needed to establish causality to asthma pathogenesis and to define the mechanisms contributing to these associations in both adult and pediatric patients. Another possible mechanism for these associations is that a person with immune function that is biased towards atopy may have both altered host defenses that increase susceptibility to bacterial and viral infections and an increased risk of developing asthma [3,78–82]. Collectively, these studies regarding chronic bacterial infection/colonization have formed the basis for randomized, placebo-controlled, double-blind clinical trials of prolonged courses of macrolide antibiotics on acute and chronic asthma control. The effect of these drugs has unfortunately been variable depending on the population [83–86].
Several mechanisms have been proposed to elucidate how respiratory viruses lead to wheezing illnesses and exacerbations of asthma. First, viral infections injure airway epithelial cells and can initiate airway edema and leakage of serum proteins into the airway. Along with shedding of infected cells into the airway, the effects can lead to obstruction and wheezing. Furthermore, virus-induced immune responses are essential to clear the viral infection, but may also contribute to symptoms and airway hyperactivity by causing an influx of inflammatory cells that negatively impact lower airway physiology. Respiratory viruses can augment airway inflammation by directly infecting lower airway tissues, or perhaps by infecting the upper airway and then initiating a systemic immune response that promotes lower airway inflammation. Environmental factors may act synergistically with viral infections and other known triggers leading to acute exacerbations. Allergic sensitization increases the risk of the development of asthma after virus-induced wheezing episodes in infancy and is strongly related to virus-induced exacerbations of asthma in older children and adults with asthma. For example, effects of viral infection on the severity of an asthma exacerbation may be augmented by exposure to allergens to which an individual is sensitized  and by exposure to increased levels of air pollutants . It is also possible that allergic sensitization alone may increase the susceptibility to viral infections such as HRVs .
Although a general cohort of adult patients with asthma does not appear to get more URIs compared with healthy cohabitants with similar exposures , observational studies in adults and children suggest that those with low vitamin D serum levels have a higher incidence of virus-induced asthma exacerbations [89–93]. The relationship between low vitamin D status and asthma is further supported by a number of observations. First, genetic polymorphisms in vitamin D receptor-dependent pathways are associated with the development of asthma [94–96]. Second, vitamin D deficiency may be related to the seasonal variation in symptomatic respiratory infections  even in southern climates where, despite greater potential for cutaneous synthesis, low vitamin D status is common [98–100]. Third, mechanistic studies have shown that vitamin D treatment increases β-defensin production [101,102], alters MHC, CD14 and TLR expression [103–105], and enhances T-regulatory cell suppression . Finally, vitamin D treatment of airway epithelial cells promotes differentiation , and in this sense may promote the healing of epithelial barrier defenses, as undifferentiated basal cells are more easily infected . These basic and clinical observations remain to determine whether vitamin D supplementation decreases the rate of infectious illnesses and/or asthma exacerbations.
Several groups have postulated that the airway epithelium regulates the immune response to environmental injury (including those induced by respiratory infection) and that there are key differences in these responses that distinguish healthy controls from patients with asthma and may even contribute to asthma inception [109,110]. Repeated asthma exacerbations damage the airway epithelium and contribute to the loss of lung function . Some studies describe patches of denuded airway in asthmatic patients at baseline with good symptom control, which are not observed in healthy controls, although these differences are not universally found [112–114]. Epithelial experiments in vitro suggest that relative to healthy controls, the asthmatic epithelial cells are slower to differentiate and form tight junctions for barrier defense, and produce numerous inflammatory mediators important for innate immunity to a variety of insults [115,116]. Denuded airways are also associated with vascular leak and cellular inflammation, contributing to worse symptom control . In addition, viral exposure may promote dysfunctional cilia-to-goblet cell transition that depends on both the EGF receptor and exposure to IL-13 .
In terms of epithelial repair mechanisms, IL-13 appears to be a key Th2 cytokine that distinguishes asthma patients in a way that may prolong the course toward restoring normal barrier function . Its production in the airway is increased in asthmatics, in part due to well-established genetic variants [120–122]. IL-13 promotes goblet cell formation with hypersecretion of mucin , at the relative expense of tight junction-forming ciliated epithelium . It is important in the epithelial cell-initiated recruitment of eosinophils via eotaxin production , and there is a general sense that this cytokine can enhance profibrotic repair . From a phenotyping perspective, a genome-wide airway epithelial cell expression array study identified three IL-13-induced genes forming a signature that distinguished asthma patients from healthy controls with the repression of these genes by inhaled corticosteroids (ICS) in a clinical trial . As the presence of IL-13 can also downregulate IFN responses, stimulation of this pathway may contribute to selective susceptibility to prolonged infections in patients with asthma .
Much attention has been focused lately on the role of IFNs produced during viral infection. After binding to intercellular adhesion molecule (ICAM)-1 or the low density lipoprotein (LDL) receptor, for major and minor group HRVs respectively, entry and uncoating occurs. IFNs are then rapidly induced by HRV-stimulated signaling by TLR3 via the transcription factor NF-κB, as well as by activating RNA helicases such as retinoic acid-induced gene (RIG)-1 or melanoma differentiation antigen (MDA)-5-induced activation of the transcription factor, interferon regulatory factor 3 . Epithelial cell production of IFN-β in particular is responsible for the stimulation of many of the genes subsequently induced by HRVs . Of significant interest, Johnston and colleagues have shown that the undifferentiated airway epithelial cell production of IFN-β and IFN-γ in response to HRVs discerns healthy subjects from asthmatics [131, 132]; however, these differences were not observed using a genome-wide expression array or candidate gene quantitative PCR . In summary, there is wide recognition that the airway epithelial cell is a key component of innate defense, that asthma-specific defects in epithelial-directed airway repair and infection response may be regulated by IL-13, and that the responses of epithelial cells to HRV infection are important to asthma; however, the mechanisms warrant further study.
The cellular inflammatory response in the upper airway may hold a key determinant to HRV control that is different in asthmatic patients. In a classic longitudinal cohort study, patients with asthma get a similar number of colds as their healthy cohabitants, but those with asthma have an approximately twofold greater risk of a lower airway infection with a greater duration and more intense symptoms , suggesting that asthmatics possess an inability to efficiently contain the virus in the initial upper airway inflammatory response. Regarding potential mechanisms, upper airway epithelial cells are more resistant to rhinoviral infection than bronchial cells; however, this occurs for both healthy and asthma subjects . Nasal chemokines have been associated with neutrophilic influx and cold symptoms . Interestingly in subjects with allergic rhinitis, three nasal challenges with allergen sufficient to promote nasal eosinophilia the week before an experimental HRV-16 cold had a delayed onset and shorter duration of cold symptoms, compared with a placebo-primed, HRV-challenged group . Upper airway neutrophil influx during a naturally acquired asthmatic viral cold has been shown to be inversely associated with the subsequent development of lower airway symptoms, although in a multivariate model a novel asthma biomarker, the pore function of the nucleotide receptor, P2X7, was more predictive of loss of control . P2X7 is a leukocyte/epithelial cell trimeric cation channel/pore that amplifies TLR-dependent immune responses in the presence of danger signals such as ATP, present in the airway at higher concentrations during allergic or viral challenges [138–141]. To summarize, the initial epithelial cell response to infection in the upper airway may be modified by several host factors important to asthma pathophysiology, with attenuated microbial clearance contributing to a greater risk of lower airway infection and asthma symptoms.
Respiratory syncytial virus and influenza infections are well-recognized causes of bronchitis, bronchiolitis and pneumonia [73,142,143]. Historically, HRV was considered to be solely an upper airway pathogen because of its association with common cold symptoms and the observation that HRV replicates best at 33–35°C, thought consistent only with the temperature of the upper airway. In fact, lower airway temperatures have been recorded using a bronchoscope equipped with a small thermistor . During quiet breathing at room temperature, airway temperatures are favorable to HRV replication down to fourth-generation bronchi, and surpass 35°C only in the periphery of the lung. Furthermore, HRV appears to replicate equally well in cultured epithelial cells derived from either upper or lower airway epithelium , although this finding is not universal . Finally, HRV has been observed in lower airway cells and secretions by several techniques after experimental inoculation [146–148]. In support of the experimental infection model data, HRV is frequently found in infants and children with lower respiratory signs and symptoms, including children hospitalized for pneumonia . In infants with recurrent respiratory symptoms, HRV was detected in lower airways by bronchial biopsy in 45%, and the majority of these HRV-positive infants also showed increased airway resistance . Viral clearance may also be affected in asthma, in that two studies with adults under conditions of stable disease have demonstrated evidence of viral pathogens in sputum samples or transbronchial lung biopsies [151,152]. Together, these findings imply that respiratory viruses, including HRV, are likely to promote wheezing illnesses and exacerbations of asthma largely by infecting lower airways and causing or augmenting lower airway inflammation, and that these pathogens may be incompletely cleared in select patients. These features and a proposed model for the epithelial cell-dependent promotion of asthma symptoms are reviewed in Figure 1.
The effect of allergic sensitization on the asthmatic airway response to viral infection has been a topic of much research. The relationship between these two factors appear to be bidirectional, as the atopic state can alter the lower airway response to viral infections [13,153], viral infections can affect the development of allergen sensitization [154,155], and synergistic interactions can emerge when individuals are exposed concurrently to both allergens and viruses [11,156,157]. As previously suggested, atopic individuals may have both altered host defenses that increase susceptibility to bacterial and viral infections, and an increased risk of developing asthma [3,78–82].
Atopy is a risk factor for the development of childhood asthma after virus-induced wheezing illnesses and many investigative groups have explored the mechanisms of this relationship . It has also been proposed that atopy may be an important predisposing factor for the development of acute bronchiolitis during RSV epidemics . Some investigators have reported that atopic parents increase the likelihood of children developing persistent wheezing [159–161], whereas others have not observed this [162,163]. Similarly, there is controversy over whether personal atopy is more prevalent after bronchiolitis [12,154,163,164]. Albeit, it is clear that children who wheeze in early life and have atopic features such as allergic sensitization, atopic dermatitis and either blood eosinophilia or allergen-specific IgE are at the highest risk for later asthma. These findings have led to the development of predictive indices to estimate the risk of asthma after wheezing in infancy [165,166].
There are data to support that allergic sensitization is a risk factor for wheezing with common cold infections in later childhood [17,167]. In an emergency department setting, risk factors associated with acute wheezing episodes were reported . These included the detection of a respiratory virus, most commonly HRV, positive allergen-specific IgE, and the presence of eosinophilia. Notably, viral infections and allergic inflammation synergistically augmented the risk of wheezing. Moreover, experimental inoculation with HRV is more likely to increase airway responsiveness in allergic individuals compared with nonallergic individuals . Finally, the risk of hospitalization among virus-infected individuals is amplified in patients who are both sensitized and exposed to respiratory allergens . These results imply that individuals with respiratory allergies or eosinophilic airway inflammation are at increased risk for viral-induced wheezing. However, this theory has not been confirmed with experimentally induced colds, as allergen administration before viral inoculation did not increase cold symptoms [136,169].
Viral infections are proposed to interact with allergic inflammation, leading to airway dysfunction through several mechanisms. Viral infections could potentially damage the barrier function of the airway epithelium, leading to an enhanced absorption of aeroallergens across the airway wall and subsequent inflammation . Moreover, the production of various cytokines (TNF-α, IL-1β and IL-6), chemokines (CCL3/MIP-1α, CCL5/RANTES, CCL2/MCP-1 and CXCL8/IL-8), leukotrienes and adhesion molecules (ICAM-1) may further upregulate cellular recruitment, cell activation and the ongoing inflammatory response . Several studies have also demonstrated that HRV infection increases airway hyperresponsiveness in patients with atopy and asthma [156,167,168,172]. Finally, a recent study has demonstrated that the use of prednisolone was associated with less recurrent wheezing in young children with HRV infection but not those with RSV or non-HRV/RSV infections. Thus, HRV infection may be a marker for wheezing children that will respond favorably to corticosteroid treatment .
Respiratory infections, and particularly those caused by viruses, are significant causes of wheezing illnesses in all ages, and progress is being made toward establishing the mechanisms by which these agents can cause acute wheezing and impact the pathophysiology of asthma. Whether there are true asthmagenic strains of these viruses will require additional epidemiological study over several cold seasons, with sampling from diverse geographic regions. Host factors likely contribute to the risk of asthma inception and exacerbation, and these contributions may also vary with respect to early- versus adult-onset disease. These include epithelial barrier defense, IL-13, interferons and/or danger receptors such as P2X7. Once these mechanisms are understood, it may be possible to identify patients who are at the greatest risk for wheezing with viral infections, or those whose virus-induced wheezing heralds the onset of asthma. This would be a key step as preventive therapy could then be focused to the groups with the greatest need.
In the next 5 years, more gene-by-environment interactions should be elucidated, particularly the way in which innate immune system defects impact the severity of viral infections and the inception of asthma. In addition, we will have an improved understanding of whether host factors such as epithelial cell function or immune response versus virulence of virus strain are important to the inception of asthma after viral infection. Identification of a pre-asthma phenotype using novel biomarkers will facilitate the improved identification of at-risk populations and the use of more effective treatment strategies.
Loren C Denlinger is supported by NHLBI grants, K23 HL081492 and P01 HL088594. Theresa W Guilbert is supported by NHLBI grants, U10 HL64305 and P01 HL070831-06A1
Financial & competing interests disclosure: The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Theresa W Guilbert, The Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, K4/944, CSC-4108, Madison, WI 53792, USA, Tel.: +1 608 263 9608, Fax: +1 608 265 0510.
Loren C Denlinger, The Department of Medicine, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, K4/912, CSC-9988, Madison, WI 53792, USA, Tel.: +1 608 261 1552, Fax: +1 608 263 3104.
Papers of special note have been highlighted as:
• of interest
•• of considerable interest